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Abstract
Purpose: This was an open-label phase 1a study assessing the maximum tolerated dose (MTD), safety, and tol-
erability of CXCR4 peptide antagonist, LY2510924, administered in combination with durvalumab in patients
with advanced refractory solid tumors.
Methods: Patients received LY2510924 at 20, 30, or 40 mg subcutaneous (SC) once daily in combination with
durvalumab at 1500 mg intravenously (IV) on day 1 of each 28-day cycle. The primary objective was to assess
the MTD and safety of LY2510924 SC daily in combination with durvalumab in patients with advanced (meta-
static and/or unresectable) solid tumors. Secondary objectives included pharmacokinetics (PK) and the antitumor
activity of LY2510924 in combination with durvalumab. Exploratory objectives were biomarker analysis, including
pharmacodynamic markers, relevant to LY2510924 and durvalumab, including immune functioning, drug
targets, cancer-related pathways, and the disease state.
Results: Nine patients (three each at 20, 30, and 40 mg) were enrolled in the study (eight patients with pancre-
atic cancer and one patient with rectal cancer). The majority of patients completed one or two cycles (100.0% ‡ 1
cycle; 88.9% ‡ 2 cycles) of LY2510924 and durvalumab. No dose limiting toxicities were reported. Most common
(>10%) treatment-emergent adverse events were injection-site reaction (44.4%), fatigue (33.3%), and increased
white blood cell count (33.3%). PK parameters for combination were similar to those reported in previous studies
when given as monotherapy. Best overall response of stable disease was observed in four (44.4%) patients and
one patient had unconfirmed partial response.
Conclusion: The recommended phase 2 dose is 40 mg SC once-daily LY2510924 in combination with
durvalumab 1500 mg IV and showed acceptable safety and tolerability in patients with advanced refractory
tumors.
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Cancer metastasis is the major cause of cancer morbid-
ity and mortality, and accounts for *90% of cancer
deaths. However, effective treatment options for ad-
vanced cancer are limited.1 The chemokine (C-X-C
motif) receptor 4 (CXCR4) and its only known ligand,
a-chemokine stromal cell-derived factor-1 (SDF-1, also
known as CXCL12), play an important role in the reg-
ulation of organ-specific metastasis, as well as in tumor
growth, invasion, survival, and angiogenesis.2 CXCR4
is functionally expressed or overexpressed in a variety
of solid tumors, lymphomas, and chronic lymphocytic
leukemias.3,4 In addition, CXCR4 and the SFD-1 axis
also play a critical role in leukocyte trafficking, T cell
infiltration, and immune response.5
Pre-clinical and clinical studies of agents that target
CXCR4 have demonstrated mobilization of immune
cells and hematopoietic stem cells (HSCs) into periph-
eral blood by altering cell homing, retention, and release
from the bone marrow compartment. The existing pre-
clinical and emerging clinical data indicate CXCR4 to be
an attractive target for antitumor drug development.5,6
LY2510924 is a potent, selective peptide antagonist
of CXCR4 both in vitro and in vivo. In several cancer
xenograft models utilizing cell lines that express high
levels of CXCR4, LY2510924 has demonstrated dose-
dependent inhibition of tumor growth and metastasis.7
Previously, in a phase 1 trial, LY2510924 was adminis-
tered at doses ranging from 1 to 30 mg as a daily sub-
cutaneous (SC) injection.8 At a dose of 30 mg/day, two
patients experienced dose-limiting toxicity (DLT) de-
fined as grade 3 increase in absolute neutrophil
count (ANC) >25,000 cells/lL for >5 days.8 In another
randomized phase 2 trial, the addition of LY2510924
20 mg SC to sunitinib in the first-line treatment of
metastatic renal cell carcinoma (RCC) was well tolerat-
ed.9 In all these clinical studies, administration of
LY2510924 was associated with a significant increase
of cluster of differentiation (CD34+) HSCs and leuko-
cytes in circulation.8,9
Durvalumab is a selective, high-affinity, human im-
munoglobulin G1 monoclonal antibody that blocks
programmed death ligand 1 (PD-L1) binding to pro-
grammed death 1 (PD-1) and CD80, allowing T cells
to recognize and kill tumor cells.10–12 While these in-
hibitors have effects in various solid tumors,13,14 PD-1
or PD-L1 inhibition has limited or no efficacy as a sin-
gle agent in pancreatic cancer,15,16 possibly, in part, due
to lack of immune cell infiltration in the tumor micro-
environment.17 Due to the critical role of CXCR4 and
SDF-1 in leukocyte trafficking and T cell infiltration,
we hypothesize that a CXCR4 inhibitor, when com-
bined with anti PD-L1 or anti PD-1 therapy, may
have the potential to enhance effects of PD-1/PD-L1
inhibitors. Indeed, CXCR4 inhibition yields increased
infiltration of T cells into tumors and tumor regression
in an in vivo pancreatic cancer mouse model.18
Here, we report the data from an open-label phase 1a
study assessing the safety and tolerability of LY2510924
in combination with durvalumab.
Methods
Study design
This study was an open-label, phase 1a, dose-
escalation trial evaluating the safety and tolerability
of LY2510924 administered in combination with dur-
valumab in patients with advanced refractory solid tu-
mors (ClinicalTrials.gov Identifier: NCT02737072).
The study protocol was approved by institutional re-
view boards/ethics committees before initiation, and
conducted in accordance with the Declaration of
Helsinki; patients provided written informed consent
before entering the study. The primary objective was
to assess the maximum-tolerated dose and safety of
LY2510924 in combination with durvalumab in pa-
tients with advanced solid tumors. Secondary objectives
included pharmacokinetics (PK) and the antitumor
activity. Exploratory objectives included pharmacody-
namic (PD) assessments of mobilization of CD34+
cells, immune cell subtyping in blood, and PD-L1 ex-
pression in tumor tissue.
Patients
Patients aged 18 years or older with a confirmed diag-
nosis of advanced solid tumor after failure of standard-
of-care therapy(s) were included in the trial. Patients
had at least one measurable lesion assessable using
standard techniques by Response Evaluation Criteria
in Solid Tumors (RECIST) v 1.1. Additional eligibility
criteria included the following: adequate organ function,
an Eastern Cooperative Oncology Group (ECOG) per-
formance status (PS) of 0 or 1, and an estimated life ex-
pectancy ‡12 weeks.
Patients were excluded from the study if they had
active autoimmune disorders or prior severe autoim-
mune or inflammatory disorders requiring immuno-
suppressive treatment. Patients requiring escalating or
chronic supraphysiologic doses of corticosteroids
(>10 mg/day of prednisone or an equivalent corticoste-
roid) for control of their disease or immunosuppressive
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agents were also excluded; in addition, patients with
prior therapy with an anti-PD-1, anti-PD-L1, anti-
PD-L2, or anti-cytotoxic T lymphocyte-associated
antigen-4 antibody or any other antibody or drug spe-
cifically targeting T cell costimulation or checkpoint
pathways.
Study dose and treatment
Patients received LY2510924 at 20, 30, or 40 mg SC
once daily in combination with durvalumab at
1500 mg, administered intravenously (IV) on day 1
of each 28-day cycle. The dose range of LY2510924
was selected based on the overall clinical information
from three prior completed studies CXAA, CXAB
(RCC), and CXAC (small-cell lung cancer).6 Lilly pro-
posed to increase the predefined ANC threshold crite-
ria to 75,000 cells/mL which was a limiting factor in
the first-in-human CXAA study.
Regarding the durvalumab dose justification, a fixed
dose of 1500 mg every 4 weeks (Q4W) [equivalent to
20 mg/kg Q4W] instead of every 2 weeks (Q2W) dos-
ing was used, given a similar area under curve (AUC),
modest differences in median peak and trough levels
at steady state, and ease of administration.
Safety assessment
Safety was assessed by monitoring adverse events
(AEs), including severity, seriousness, and the possible
relation to study drug, dose adjustments, DLTs, clinical
laboratory test results, vital signs, electrocardiogram
readings, ophthalmological assessments, and dermato-
logical evaluations. All AEs observed in the study were
graded using the Common Terminology Criteria for
Adverse Events (CTCAE) version 4.03.
Efficacy assessment
Overall response rate, duration of response, and dura-
tion of stable disease were evaluated for every two cy-
cles. Both tumor markers and evaluation of PS by the
ECOG scale were also used as response assessment.
Biomarkers/PD assessment
Blood collection and tumor biopsies were conducted
to assess PD effect and biomarker levels whenever
possible. The primary PD biomarker was to quantify
LY2510924 stimulatory effects on the mobilization
of CD34+ cells as an indirect reflection of CXCL12/
CXCR4 axis inhibition. Immunophenotyping for
CD34+ cells was performed using flow cytometry on
samples obtained at baseline (within 7 days of day 1
in cycle 1) and at multiple time points while on
study. In addition, the blood samples to identify and
determine the percentages and absolute counts of T,
B, and natural killer (NK) cells as well as the CD4+
and CD8+ subpopulations of T cells expressing Ki67
and HLA-DR markers were obtained at baseline and
while on study. In addition, ANC and absolute lym-
phocyte counts were obtained from a standard local
blood test.
Tumor tissues at baseline (obtained from a newly
obtained core or excisional biopsy of tumor lesion or
archived biopsy) were tested for PD-L1 expression
using the Ventana PD-L1 (SP263) immunohistochem-
istry (IHC) assay on an automated BenchMark ULTRA
platform, using the anti-human PD-L1 rabbit mono-
clonal antibody. PD-L1 expression on tumor cells was
calculated as the proportion of cells expressing PD-L1
at any intensity above background staining. The data
analysis was descriptive.
Pharmacokinetic assessments
Blood samples were drawn from all patients for the as-
sessment of LY2510924 in plasma and durvalumab
concentrations in serum at prespecified time points.
The PK of LY2510924 was assessed through intensive
sampling, and the PK parameter estimates were calcu-
lated by standard noncompartmental methods of anal-
ysis. PK data for durvalumab were summarized by
sampling time points, and a formal noncompartmental
analysis was not conducted. Samples were analyzed
using a validated liquid chromatography with tandem
mass spectrometry. Summary statistics was tabulated
for the PK parameters of LY2510924 and durvalumab
by dose and study day.
Results
Patients
A total of nine patients (three patients each in
LY2510924 at 20, 30, and 40 mg) were enrolled in the
study (eight patients with pancreatic cancer and one
patient with rectal cancer). All the patients were
white, 66.7% were male and 55.6% had an ECOG PS
of 1 (Table 1). The median age of the patients was 53
years (range 33–77). The majority of the patients
(n = 6; 66.7%) had received ‡3 prior regimens. All the
patients discontinued study treatment due to progres-
sive disease. The postdiscontinuation follow-up ended
as a result of patient death due to PD (n = 6, 66.7%)
and lost to follow-up (n = 3, 33.3%).




The majority of patients completed one or two cycles
(100.0% ‡ 1 cycle; 88.9% ‡ 2 cycles) of LY2510924 and
durvalumab, with a median duration of treatment of
102 days for LY2510924 and 110 days for durvalumab.
Safety
No DLTs were reported in this study at any of the dose
levels, and there were no AEs resulting in death or dis-
continuation from the study treatment. All patients
(n = 9) experienced ‡1 treatment-emergent adverse
event (TEAE) possibly related to the study treatment.
The most common (>10%) TEAEs related to study
treatment were injection-site reaction (n = 4; 44.4%),
fatigue (n = 3; 33.3%), and increased white blood cell
count (n = 3; 33.3%) (Table 2).
Four (44.4%) patients experienced at least one
TEAE that was ‡grade 3, of which two (22.2%) were
assessed as possibly related to the study treatment
(one each from the 30 mg and the 40 mg cohort):
grade 4 pancreatic carcinoma metastatic and grade
3 leukocytosis; these are the only two treatment-
related serious adverse events (SAEs) of the five
SAEs that were reported on this trial. The event of
‘‘pancreatic cancer metastatic’’ was reported in one
patient who developed several palpable nodules on
the thigh that appeared as rim enhancing intramuscu-
lar nodules on computed tomography (CT) that could
be consistent with metastatic disease.
LY2510924 injections were administered to this spe-
cific area on the upper thigh as opposed to the abdo-
men, which was the recommended location. Given
that biopsy of these lesions was not performed, it
could not be determined definitively that this repre-
sented intramuscular necrotic areas from intramus-
cular injections of LY2510924 versus metastatic
disease. This event was assessed as SAE since no le-
sions were found outside the area where LY2510924
was administered, although no other similar events
have been reported in this study or previously in
any other studies involving LY2510924.
Table 1. Patient Baseline Characteristics
Characteristics N (%)
Age, years
Median (range) 53 (33–77)
<65 Years 7 (77.8)
















‡1 Prior systemic therapy
Adjuvant 4 (44.4)
Neoadjuvant 5 (55.5)
Locally advanced 1 (11.1)
Metastatic 7 (77.8)
ECOG, Eastern Cooperative Oncology Group; PS, performance status.
Table 2. Most Common (‡10%) Treatment-Emergent Adverse Events Related to Study Treatment
DURV1500-LY
20 mg/day (N = 3)a
DURV1500-LY
30 mg/day (N = 3)a
DURV1500-LY


























Injection-site reaction 1 (33.3) 0 (0) 1 (33.3) 1 (33.3) 0 (0) 1 (33.3) 2 (66.7) 0 (0) 2 (66.7) 4 (44.4) 0 (0) 4 (44.4)
Fatigue 0 (0) 0 (0) 0 (0) 2 (66.7) 0 (0) 2 (66.7) 1 (33.3) 0 (0) 1 (33.3) 3 (33.3) 0 (0) 3 (33.3)
White blood cell
count increased
2 (66.7) 0 (0) 2 (66.7) 1 (33.3) 0 (0) 1 (33.3) 0 (0) 0 (0) 0 (0) 3 (33.3) 0 (0) 3 (33.3)
Decreased appetite 0 (0) 0 (0) 0 (0) 2 (66.7) 0 (0) 2 (66.7) 0 (0) 0 (0) 0 (0) 2 (22.2) 0 (0) 2 (22.2)
Back pain 0 (0) 0 (0) 0 (0) 1 (33.3) 0 (0) 1 (33.3) 1 (33.3) 0 (0) 1 (33.3) 2 (22.2) 0 (0) 2 (22.2)
Hypothyroidism 0 (0) 0 (0) 0 (0) 1 (33.3) 0 (0) 1 (33.3) 1 (33.3) 0 (0) 1 (33.3) 2 (22.2) 0 (0) 2 (22.2)
Constipation 0 (0) 0 (0) 0 (0) 2 (66.7) 0 (0) 2 (66.7) 0 (0) 0 (0) 0 (0) 2 (22.2) 0 (0) 2 (22.2)
Nausea 0 (0) 0 (0) 0 (0) 2 (66.7) 0 (0) 2 (66.7) 0 (0) 0 (0) 0 (0) 2 (22.2) 0 (0) 2 (22.2)
Leukocytosis 0 (0) 0 (0) 0 (0) 0 (0) 1 (33.3) 1 (33.3) 0 (0) 0 (0) 0 (0) 0 (0) 1 (11.1) 1 (11.1)
Neutropenia 0 (0) 0 (0) 0 (0) 0 (0) 1 (33.3) 1 (33.3) 0 (0) 0 (0) 0 (0) 0 (0) 1 (11.1) 1 (11.1)
Pancreatic carcinoma
metastaticb
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 1 (33.3) 1 (33.3) 0 (0) 1 (11.1) 1 (11.1)
aDose of durvalumab kept constant at 1500 mg every 4 weeks for all cohorts.
bNodules in injection area defined as metastases by investigator. See the Safety section for details.
DURV, durvalumab; LY, LY2510924.




There were no confirmed complete or partial responses
reported in the study. Best overall response of stable
disease was observed in four (44.4%) patients. Four pa-
tients had stable disease (two patients with pancreatic
cancer and one patient with rectal cancer in the
20 mg cohort and one patient with pancreatic cancer
in the 30 mg cohort). One of these patients with stable
disease with microsatellite stable (20 mg) had an un-
confirmed partial response based on a CT-scan at the
end of cycle 6 showing a 31% reduction in target le-
sions. Five patients had progressive disease as best re-
sponse (2 in the 30 mg cohort and 3 in the 40 mg
cohort; Figs. 1 and 2).
Pharmacokinetic assessments
LY2510924. LY2510924 PK data were available from
all nine patients enrolled. The dose levels evaluated
were 20, 30, and 40 mg daily injection on a 28-day
cycle, dosed continuously. LY2510924 was quickly
absorbed after SC administration with a biphasic,
dose-dependent decline of LY2510924 serum concen-
tration. Maximum concentration (Cmax), t1/2, and
AUC increased with dose, although the 20- and 30-mg
dose groups were not well separated based on a small
number of patients. LY2510924 mean apparent clear-
ance and volume of distribution were estimated to be
7 L/h and 59 L, respectively. A high level of PK variabil-
ity was observed, with *60% on Cmax and 69% on
FIG. 1. Napoleon plot of treatment duration.
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AUC (Table 3 and Fig. 3). These results were consistent
with the LY2510924 PK profile.
Durvalumab. PK data were available for all nine pa-
tients following treatment with 1500 mg Q4W of dur-
valumab administered as an IV infusion over 60 min.
Following 1500 mg Q4W durvalumab, the geometric
mean (n, %CV) of peak concentrations on week 0
and 12 was 418 (n = 8, 33.2%) and 549 (n = 4, 30.8%)
lg/mL, respectively. The geometric mean (n, %CV)
of trough concentrations on week 4, 8, 12, and 20
was 106 (n = 8, 50.3%), 133 (n = 4, 58.4%), 126 (n = 4,
46.8%), and 74.9 (n = 1) lg/mL, respectively (Fig. 4),
and was consistent with the durvalumab PK profile.
PD assessments. A rapid and sustained increase in
CD34+ HSCs was observed in the peripheral blood
FIG. 2. Swim plot of overall survival and progression-free survival.
Table 3. Mean LY2510924 Pharmacokinetic Parameters
Following a 20-, 30-, or 40-mg Dose
Geometric mean (CV%)
LY2510924
dose (mg/day) 20 (n = 3) 30 (n = 3) 40 (n = 3)
Day 1
Cmax (ng/mL) 746.68 (56) 682.34 (19) 1857.93 (53)
Day 15
Cmax (ng/mL) 366.67 (169) 847.27 (15) 1678.77 (54)
AUC (0–inf)
(ng · h/mL)
1960 (258) 4320 (11) 6210-170000a
CL/F (L/h) 10.8 (243) 7.37 (10) 4.10 (52)
t1/2b (h) 5.11 (3.11–7.53) 5.98 (5.43–7.15) 7.01–9.14a
Vd/F (L) 79.5 (137) 63.6 (16) 36.1–71.2a
an = 2, individual values reported.
bGeometric mean (range).
%CV, coefficient of variation; AUC(0–inf), area under the plasma concen-
tration time curve from time zero to infinity; CL/F, apparent clearance; Cmax,
maximum plasma concentration; N, number of patients who received
dose; t1/2:elimination half-life; Vd/F, apparent volume of distribution.
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beginning 2 h following treatment with LY2510924 and
durvalumab (Fig. 5). There did not appear to be a rela-
tionship between CD34+ counts and LY2510924 dose.
The CD34 absolute counts increased in all dose cohorts
beginning at cycle 1 day 1 (C1D1) 2 h following treat-
ment and remained increased through C1D16; and in
general, the CD34 absolute counts increased in dose co-
horts with evaluable data over the course of the study
(C2D1, C3D1, and C4D1). The numbers of neutrophils
and lymphocytes increased in the peripheral blood in
subjects in all dose cohorts by C1D15 and remained
increased over the course of the study (Figs. 6 and 7).
In addition, LY2510924 and durvalumab mobilized im-
mune cells and triggered an increase in monocytes, T, B,
FIG. 3. Mean and SD of LY2510924 pharmacokinetic profiles following a 20-, 30-, or 40-mg subcutaneous
dose, (a) cycle 1 day 1 and (b) day 15 coadministered with durvalumab infusion on day 1 of cycle 1. SD,
standard deviation.
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and NK cells (antibodies) in peripheral blood in all dose
cohorts at C1D15. No clear dose dependency was ob-
served and data were sparse after cycle 1 (data not
shown).
PD-L1 expression. PD-L1 protein at baseline was
evaluated for six patients (one patient provided
both archival tissue and newly obtained biopsy)
in three archival tissue sections and four newly
obtained biopsies using a fully validated IHC test
that determines levels of PD-L1 expression on
both tumor cells (TC+) and infiltrating immune
cells (IC+). A small set of samples, including
fresh and archival biopsies, was analyzed, and no
FIG. 4. Mean (–SD) serum PK profile of durvalumab following 1500 mg Q4W IV administration. IV,
intravenously; PK, pharmacokinetics.
FIG. 5. Summary of CD34+ absolute counts (109/L) versus time by dose. At pretreatment, mean CD34+ count
was 1.4 (SD = 0.5), 2.3 (SD = 1.6), and 1.1 (SD = 0.3) in the 20, 30, and 40 mg/day dose cohorts, respectively.
At C1D15, mean change (increase) from pretreatment in CD34+ count was 4.5 (SD = 2.8), 20.9 (SD = 18.7), and
9.7 (SD = NA) in the 20, 30, and 40 mg/day dose cohorts, respectively.
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apparent correlation between PD-L1 expression
and clinical outcome was observed. The percentage
TC+ with PD-L1 membrane staining ranged from
0% to 2%, and four of seven samples did not
have PD-L1 expression. PD-L1 TC+ cases included
one patient with stable disease and PD, respectively.
The percentage IC+ with PD-L1 membrane staining
ranged from 0% to 60% and four of seven samples
greater than 25% of the immune cells exhibit
PD-L1 staining.
FIG. 6. Summary of ANC versus time by dose. At pretreatment, mean ANC was 6.7 (SD = 3.7), 5.4 (SD = 1.8),
and 3.6 (SD = 1.8) in the 20, 30, and 40 mg/day dose cohorts, respectively. At C1D15, mean change (increase)
from pretreatment in ANC was 2.6 (SD = 0.8), 3.7 (SD = 1.9), and 3.2 (SD = 1.1) in the 20, 30, and 40 mg/day dose
cohorts, respectively. ANC = absolute neutrophil count.
FIG. 7. Summary of ALC versus time by dose. At predose, mean ALC was 1.6 (SD = 0.98), 1.2 (SD = 0.3), and 1.2
(SD = 0.29) in the 20, 30, and 40 mg/day dose cohorts, respectively. At C1D15, mean change (increase) from
predose in ALC was 2.4 (SD = 1.3), 2.3 (SD = 0.4), and 2.5 (SD = 0.4) in the 20, 30, and 40 mg/day dose cohorts,
respectively. ALC, absolute lymphocyte count.




LY2510924 is a potent and selective peptide antagonist
of CXCR4 with demonstrated antitumor activities in
multiple solid tumor xenograft models, and several
pre-clinical trials of CXCR4 inhibition have dem-
onstrated significant antitumor efficacy.7,19,20 Combi-
nation studies with PD-1 inhibition have received
attention, given that pre-clinical studies have demon-
strated synergy between CXCR4 and PD-1/PD-L1 in-
hibitors. For example, in a pancreatic cancer model, T
cells were typically localized to tumor microenvironment
stroma, and the addition of the CXCR4 small-molecule
inhibitor AMD3100 led to T cell redistribution and
rapid accumulation near tumors, enhancing the antitu-
mor efficacy of an anti-PD-L1 monoclonal antibody
combination regimen.13
Similarly, in a syngeneic squamous cell carcinoma
model, although a single agent of LY2510924 or anti
PD-1 antibody showed minimal activity, their combi-
nation displayed significant synergy and resulted in
complete tumor growth regression. Importantly,
LY2510924 mobilized the CD34+ HSCs and leuko-
cytes, increasing these cell counts in circulation.5,8
Treatment in these models with CXCR4 antagonists
resulted in selective reduction of intratumor regulatory
T cells and concomitant increases in T cell-mediated an-
titumor immune responses, and synergy with PD-1 in-
hibitors supported the clinical evaluation of LY2510924
and durvalumab in this study.
Based on this phase 1 study, the safety profile for
LY2510924 was acceptable for an advanced cancer pop-
ulation. There were no DLTs identified in any of the co-
horts. In addition, there were few SAEs, with only two
SAEs related to treatment, specifically grade 3 neutrope-
nia and grade 4 ‘‘pancreatic carcinoma metastatic.’’
The PK parameters for LY2510924 and durvalumab
given in combination are similar to those reported in
previous studies when given as monotherapy. Within
the dose range explored (20–40 mg/day), LY2510924
Cmax and AUC values increased with dose. The PD pa-
rameters for LY2510924 given in combination with
durvalumab were similar to those in monotherapy as
reported previously.6 Elevations of similar magnitude
and temporal pattern were seen across all leukocyte
subsets tested—neutrophils, lymphocytes, monocytes,
T, B, NK cells, and CD34+ HSCs. In both the previ-
ously reported monotherapy study and this study, a
rapid and sustained PD response was observed with
treatment as demonstrated by mobilization of leuko-
cytes and stem cells, a clear indication of target modu-
lation. In a monotherapy study of LY2510924, there
was a dose relationship between CD34+ counts in pe-
ripheral blood at 24 h as the doses increased from 1.0
to 10 mg/day.6 However, this response seemed to dimin-
ish at doses >10 mg/day, including at the 30 mg/day
dose explored in this study. This study did not reveal
a clear dose–response for the CD34+ levels at the
three doses tested when LY2510924 was given in com-
bination with durvalumab. Similarly, the absolute
numbers of neutrophils and lymphocytes increased
in the peripheral blood in subjects in all dose cohorts,
with a trend toward dose–response relationship only
noted between 20 and 30 mg for ANC. This trend is
difficult to conclude given the small number of pa-
tients and blood collection, as well limited tumor tis-
sue for PD and target modulation evaluation. Despite
these limitations, the adverse events did not increase
with the LY2510924 dose. Based on safety alone, a
dose of 40 mg SC daily LY2510924 in combination
with durvalumab is recommended. In future studies,
it is imperative to obtain tumor biopsies to confirm
the hypothesis that CXCR4 inhibition is associated
with increased T cell trafficking to the tumor microen-
vironment, and further evaluate 40 mg dose as the ap-
propriate dose to accomplish this task. Given the
paucity of patients at the RP2D, a larger expansion
in pancreatic cancer at the appropriate dose would
be necessary to address whether the combination of
CXCR4 inhibitor with a PD-1/PD-L1 agent would
be efficacious, particularly given the unconfirmed par-
tial response noted in dose escalation.
Conclusion
The safety profile for LY2510924 was acceptable in the
advanced cancer population. Although only one patient
had unconfirmed partial response and four patients had
stable disease, the PK profiles for LY2510924 and dur-
valumab, given in combination, were similar to those
reported in monotherapy setting. The study confirms
the acceptable safety and tolerability of LY2510924 in
combination with durvalumab in patients with ad-
vanced refractory tumors. The recommended phase 2
dose is 40 mg SC once daily LY2510924 in combination
with durvalumab 1500 mg IV Q4W.
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Abbreviations Used
ALC ¼ absolute lymphocyte count
ANC ¼ absolute neutrophil count
AUC ¼ area under curve
CT ¼ computed tomography
CXCR4 ¼ chemokine (C-X-C motif ) receptor 4
DLT ¼ dose-limiting toxicity
ECOG ¼ Eastern Cooperative Oncology Group
HSC ¼ hematopoietic stem cell
IHC ¼ immunohistochemistry
IV ¼ intravenously
MTD ¼ maximum tolerated dose
PD ¼ pharmacodynamics
PD-1 ¼ programmed death 1
PD-L1 ¼ programmed death ligand 1
PK ¼ pharmacokinetics
PS ¼ performance status
RCC ¼ renal cell carcinoma
SAE ¼ serious adverse event
SC ¼ subcutaneous
SD ¼ standard deviation
SDF-1 ¼ stromal cell-derived factor-1
TEAE ¼ treatment-emergent adverse event
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